Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.61 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.53 |
| ▸ | POLA1 | P09884 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685346 | 0.90 | KDM4E (0.59) | KDM4ETAS1R3TAS1R1P2RY1POLA1 | |
| SCHEMBL29559302 | 0.86 | POLA1 (0.66) | KDM4ETAS1R3TAS1R1POLA1 | |
| SCHEMBL890293 | 0.86 | POLA1 (0.66) | KDM4ETAS1R3TAS1R1POLA1 | |
| SCHEMBL31685240 | 0.86 | P2RY1 (0.51) | KDM4ETAS1R3TAS1R1P2RY1 | |
| SCHEMBL25139386 | 0.85 | KDM4E (0.62) | KDM4ETAS1R3TAS1R1P2RY1POLA1 | |
| SCHEMBL31685734 | 0.84 | TAS1R3 (0.75) | KDM4ETAS1R3TAS1R1P2RY1POLA1 | |
| SCHEMBL2985702 | 0.84 | POLB (0.61) | KDM4EP2RY1POLB | |
| SCHEMBL31685625 | 0.83 | P2RY1 (0.51) | KDM4EP2RY1POLA1POLB | |
| SCHEMBL31685416 | 0.83 | TAS1R3 (0.75) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL23225351 | 0.81 | KDM4E (0.77) | KDM4ETAS1R3TAS1R1P2RY1POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | KDM4E 3958/4885TAS1R3 3879/4885TAS1R1 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.